Project Grant R21AI193553
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $790,913 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the molecular and cellular mechanisms by which gut commensal microbiota-specific T cells drive intestinal and neuroinflammation. The project investigates how segmented filamentous bacteria (SFB)-specific CD4 T cells, initially generated in gut-draining mesenteric lymph nodes and intestines in...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $243,824 on May 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how gut bacteria enzymatically inactivate glucocorticoids and thereby exacerbate inflammatory bowel disease. The project examines a novel bacterial pathway in which steroid-metabolizing enzymes present in elevated abundance within IBD patient microbiomes convert active glucocorticoids to...
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded the University of Florida Division of Sponsored Research $392,142 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanoparticle therapeutics for inflammatory bowel disease. The award funds development of an off-the-shelf therapeutic approach using polysaccharide A (PSA)–derived nanoparticles from commensal...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $1,177,657 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the biophysical and structural basis of T cell selection at the intersection of conventional and regulatory T cell repertoires. The research addresses autoimmune disease pathogenesis by examining how CD4+ T cells recognize peptide antigens complexed with MHC class II molecules through the T...
- The National Institute of Allergy and Infectious Diseases awarded $423,500 to Loyola University of Chicago Health Sciences Campus on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R21AI190998. The award funds research to define the mechanism of central nervous system inflammation induced by colitis in inflammatory bowel disease models. The recipient will investigate how colitis triggers CNS inflammasome activation, seeking to identify...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $236,407 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural basis of ARMA-mediated resistance to aminoglycoside antibiotics targeting the bacterial ribosome. The research addresses how ARMA methyltransferases confer high-level resistance to aminoglycosides—a cornerstone class of ribosome-binding antibacterial drugs used...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $667,630 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research decoding gamma-delta T cell selection and functional maturation through IL17RA, identified as a novel superantigen-like gamma-delta T cell receptor ligand. The project investigates endogenous ligands that shape gamma-delta T cell repertoire, functional properties, and tissue localization....
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $440,908 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify inhibitors of bacterial peptidyl-tRNA hydrolase (PTH). The recipient will synthesize and optimize derivatives of PTH inhibitor compounds with sub-micromolar IC50 values to enhance their activity against Klebsiella pneumoniae PTH and improve cellular uptake. The work includes expanding...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University a $1,279,395 cooperative agreement on August 1, 2026, to investigate fundamental mechanisms governing the induction of antigen-specific IgA in the gastrointestinal tract under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research project examines two distinct pathways generating affinity-matured gut IgA following oral immunization with protein antigens. The first pathway,...
- The National Institute of Allergy and Infectious Diseases awarded New York University a Project Grant of $791,797 on February 4, 2026, to investigate intestinal programming of gut-associated germinal centers under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research examines how the intestinal microbiota directs differential programming of local B cell responses toward production of regulatory immunoglobulin A (IgA) in gut-associated germinal centers. IgA, produced by...
The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Illinois $200,413 on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R21AI193553. The award funds research targeting GPR15, a chemoattractant receptor implicated in inflammatory bowel disease pathology. The research seeks to develop reagents and approaches to specifically modulate GPR15 activity as a novel therapeutic strategy for IBD patients with primary nonresponse or secondary loss of response to conventional medications. The work builds on evidence that GPR15-mediated T cell homing to the colon drives disease pathology and that genetic disruption of GPR15 prevents colitis in mouse models. Performance takes place in Chicago, Illinois, with a period of performance from award date through July 31, 2028. This is a Project Grant, the assistance type used by NIAID for competitive research applications evaluated on scientific merit, technical adequacy, investigator competency, facility adequacy, budget justification, and relevance to program objectives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $200.4k | 8/5/26 |